Bob Duggan, Summit Therapeutics CEO
September 8, 2024 11:39 AM EDTUpdated September 9, 06:54 AM
R&D
China

Sum­mit's Phase 3 da­ta back up biotech's boasts of beat­ing Keytru­da in lung can­cer

Andrew Dunn

Senior Biopharma Correspondent

A few months af­ter Sum­mit Ther­a­peu­tics shocked the on­col­o­gy world with an ear­ly claim that its lung can­cer drug ivonescimab had beat­en …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

FDA tells on­col­o­gy com­pa­nies how to run mul­ti-re­gion­al can­cer tri­als with a US ap­proval in mind

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times